BC Innovations | Sep 20, 2018
Distillery Therapeutics

Autoimmune disease

INDICATION: Multiple sclerosis (MS) Mouse studies suggest ablating meningeal lymphatic vessels with Visudyne verteporfin could help treat MS. In the experimental autoimmune encephalomyelitis (EAE) mouse model of MS, injection into the cisterna magna of Visudyne...
BC Innovations | Jul 26, 2018
Targets & Mechanisms

PureTech plumbs the brain

PureTech Health plc is backing a new way of thinking about Alzheimer’s disease that positions it primarily as a problem of poor drainage, building on the recent discovery of lymphatic vessels in the brain by...
BC Innovations | Jan 25, 2017
Distillery Therapeutics

Cancer

INDICATION: Breast cancer Patient sample, cell culture and mouse studies suggest inhibiting the GCCR - YAP1 signaling axis could help treat breast cancer. In patients, high GCCR signaling activity in tumors was associated with high YAP1...
BC Innovations | Jan 11, 2017
Distillery Therapeutics

Cancer

INDICATION: Liver cancer Patient sample, cell culture and mouse studies suggest inhibiting SMARCA2 or its downstream effector YAP1 could help treat hepatocellular carcinoma (HCC). In patient samples, levels of SMARCA2 and YAP1 were higher in...
BC Innovations | Oct 13, 2016
Distillery Therapeutics

Therapeutics: Yes-associated protein 1 (YAP1; YAP); WW domain containing transcription regulator 1 (WWTR1; TAZ)

Neurology INDICATION: Pain Rat studies suggest inhibiting YAP1 or its paralog WWTR1 could help treat neuropathic pain. In a rat model of peripheral nerve ligation-induced neuropathic pain, siRNA targeting YAP1 delayed the onset of mechanical...
BC Innovations | Oct 6, 2016
Distillery Therapeutics

Therapeutics: Yes-associated protein 1 (YAP1; YAP); glutaminase (GLS)

Cardiovascular disease INDICATION: Hypertension Rat studies suggest inhibiting YAP or GLS could help treat pulmonary arterial hypertension (PAH). In a rat model of PAH, Visudyne verteporfin, a YAP inhibitor, decreased pulmonary vascular proliferation and remodeling,...
BC Innovations | Sep 1, 2016
Distillery Therapeutics

Therapeutics: Yes-associated protein 1 (YAP1; YAP); p21 protein (Cdc42 Rac)-activated kinase 1 (PAK1)

Hepatic disease INDICATION: Liver fibrosis Cell culture and mouse studies suggest inhibiting YAP1 or PAK1 could help treat liver fibrosis. In activated rat primary liver myofibroblasts, the YAP1 inhibitor Visudyne verteporfin or a PAK1 inhibitor...
BC Innovations | Oct 1, 2015
Distillery Therapeutics

Therapeutics: Yes-associated protein 1 (YAP1; YAP)

Cancer INDICATION: Prostate cancer Cell culture, mouse and patient sample studies suggest inhibiting YAP1 could help treat prostate cancer. Prostate tissue levels of YAP1 were higher in prostate cancer patients than in healthy controls. In...
BC Week In Review | Oct 20, 2014
Clinical News

Lucentis ranibizumab regulatory update

FDA accepted and granted Priority Review to an sBLA from Roche's Genentech unit for Lucentis ranibizumab to treat diabetic retinopathy. The PDUFA date is Feb. 6, 2015. Separately, Health Canada approved Lucentis to treat visual...
BC Week In Review | Sep 30, 2013
Clinical News

Lucentis ranibizumab: Phase III data

The double-blind, international, Phase III RADIANCE trial in 277 patients with visual impairment due to CNV secondary to pathologic myopia showed that both dose regimens of 0.5 mg intravitreal Lucentis met the primary endpoint of...
Items per page:
1 - 10 of 412